BMRNBioMarin Pharmaceutical Inc.

Healthcare

$54.80+0.81% 1Y

$54.80

$49.6752 weeks$70.23

Is the price fair?

Fair

Neither cheap nor expensive: modest expectations priced in, but at the top of its own P/E range and rich vs its sector.

1 good, 2 to watch

What the price assumes~+2% a year

Priced for ~2% a year FCF growth. The price demands less than its three-year revenue growth of 15% a year, expectations look modest.

Vs its own P/E rangedearer than 81% of its own historyderived

Expensive vs its own history: P/E 148.1 vs a 42.3 median over 21 quarters (+250% vs median).

Vs sector (EV/EBIT)101.3×

Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.

Unless marked, from derived, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)bottom 3% of the market

FCF yieldbetter than 68% of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What BMRN's price assumes

BioMarin Pharmaceutical Inc. trades at 148× earnings against 18.8× for the median Biotechnology name, more expensive than its own group.

148

Trailing P/E · Biotechnology median 18.8 · 7.87× the median: the market pays up for this one

Price / sales: 3.25
Price / sales · today's price, trailing year to Jun 30, 2026
Free cash flow yield: 6.7%
Free cash flow yield · Biotechnology median 3.6%
Growth the price implies: +1.8%
Growth the price implies · The price pays for +1.8% free cash flow growth a year for a decade; the business has delivered +145% a year over the last three.